Major adverse cardiovascular, thromboembolic and malignancy events in the filgotinib rheumatoid arthritis and ulcerative colitis clinical development programmes

By sjmartinez • March 5, 2025

Mariette X, Borchmann S, Aspeslagh S, Szekanecz Z, Charles-Schoeman C, Schreiber S, Choy EH, Peyrin-Biroulet L, Schmalzing M, Tanaka Y, Ten Cate H, Westhovens R, van der Woude CJ, Ekoka Omoruyi EV, Faes M, Masior T, Van Hoek P, Watson C, Rudolph C, Stallmach A. Major adverse cardiovascular, thromboembolic and malignancy events in the filgotinib rheumatoid arthritis and ulcerative colitis clinical development programmes. RMD Open. 2025 Mar 4;11(1):e005033. doi: 10.1136/rmdopen-2024-005033. PMID: 40037922; PMCID: PMC11881192.

Tags: Antirheumatic Agents, Arthritis, Inflammation, Publications, Rheumatoid, Rheumatology

cfDNA derived gene signatures as surrogate for microvascular invasion in HCC

Gong R, Wang L, Xue D, Cai J, Jiang Y, Huang J, Zhu J, Li Z, Ke A, Shi G, Wang J, Wang W, Zheng[...]

Hidradenitis in Pediatrics

Dhillon S, Horneck N, Smogorzewski J. Hidradenitis in Pediatrics. Adv Pediatr. 2026 Aug;73(1):295-307. doi: 10.1016/j.yapd.2025.12.007. Epub 2026 May 21. PMID: 42481098.

Impact of antenatal screening for Chlamydia and Gonorrhea on pregnancy outcomes in South African women

Nyemba DC, de Voux A, Mvududu R, Peters RPH, Delany-Moretlwe S, Johnson LF, Coates TJ, Myer L, Davey DLJ. Impact of antenatal screening for Chlamydia[...]